Child mortality has been halved in the last 25 years. Building on this progress, new innovations in immunization are working ...

The medicines regulator has flagged up a small increased risk of Guillain-Barré syndrome after RSV vaccination in adults over ...

With the 2025 influenza season starting earlier than usual, the NICD urges South Africans to stay vigilant against seasonal viruses like flu and RSV. Learn about the symptoms, preventive measures, and ...

Respiratory syncytial virus (RSV) infections were associated with significantly increased risk for complications beyond ...

RSV is causing thousands of infant deaths in India yearly, yet remains underdiagnosed. Experts stress the urgent need for ...

Failure to recognize and resolve problems in an honest and evidence-based manner is the root cause of increasing vaccine ...

The RSV vaccination eligibility age has been lowered from 60 years to 50 years according to an update on the CDC website.

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

Test positivity for common cold coronaviruses significantly declined following widespread SARS-CoV-2 infection and COVID-19 ...

Adults as young as 50 may now qualify for an RSV vaccine if they have certain health conditions, according to a quiet update ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

Merck & Co., Inc. (NYSE:MRK) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 26, Merck & Co., Inc.